[1]邵毅,李乐妍,魏红.糖尿病黄斑水肿的诊断和治疗进展[J].眼科新进展,2022,42(11):841-846.[doi:10.13389/j.cnki.rao.2022.0174]
　SHAO Yi,LI Leyan,WEI Hong.Research progress in diagnosis and treatment of diabetic macular edema[J].Recent Advances in Ophthalmology,2022,42(11):841-846.[doi:10.13389/j.cnki.rao.2022.0174]
点击复制

糖尿病黄斑水肿的诊断和治疗进展/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
42卷
期数:
2022年11期
页码:
841-846
栏目:
述评
出版日期:
2022-11-05

文章信息/Info

Title:
Research progress in diagnosis and treatment of diabetic macular edema
作者:
邵毅; 李乐妍; 魏红
330006　江西省南昌市，南昌大学第一附属医院眼科
Author(s):
SHAO Yi; LI Leyan; WEI Hong
Department of Ophthalmology,the First Affiliated Hospital of Nanchang University,Nanchang 330006,Jiangxi Province,China
关键词:
糖尿病黄斑水肿; 糖尿病视网膜病变; 光学相干断层扫描; 荧光素眼底血管造影
Keywords:
diabetic macular edema;  diabetic retinopathy;  optical coherence tomography;  fundus fluorescein angiography
分类号:
R777.34
DOI:
10.13389/j.cnki.rao.2022.0174
文献标志码:
A
摘要:
糖尿病黄斑水肿（DME）的发病率正逐渐上升，其作为导致糖尿病患者视力不可逆丧失的主要原因，一直受到医学研究者的关注。目前，在应用诸如光学相干断层扫描和抗血管内皮生长因子等针对DME的诊疗方法的同时，多种新兴的解决方案正在被研发。因此，本文将对现有DME的诊断和治疗方案进行总结讨论，以期为未来DME诊疗标准的统一奠定基础。
Abstract:
The incidence rate of diabetic macular edema (DME) is rising. As the main cause for irreversible loss of vision in diabetic patients, DME has been getting more attention of medical researchers. In addition to existing optical coherence tomography and anti-vascular endothelial growth factor therapies for DME, a variety of new solutions are being developed. This article summarizes and discusses current diagnostic and therapeutic methods for DME, laying a foundation for its unified diagnosis and treatment in the future.

参考文献/References:

［1］　LEE R,WONG T Y,SABANAYAGAM C.Epidemiology of diabetic retinopathy,diabetic macular edema and related vision loss［J］.Eye Vis (Lond),2015,2(1):17.
［2］　DUH E J,SUN J K,STITT A W.Diabetic retinopathy:current understanding,mechanisms,and treatment strategies［J］.JCI Insight,2017,2(14):e93751.
［3］　邵毅,周召,葛倩敏.糖尿病视网膜病变及黄斑水肿诊疗规范:英国皇家眼科医师学会指南解读［J］.眼科新进展,2021,41(7):601-607.
SHAO Y,ZHOU Z,GE Q M.Diagnostic and therapeutic norms for diabetes retinopathy and macular edema:interpretation of the guidelines of the royal society of ophthalmologists［J］.Rec Adv Opthalmol,2021,41(7):601-607.
［4］　MOOKIAH M R K,ACHARYA U R,CHUA C K,LIM C M,NG E Y,LAUDE A.Computer-aided diagnosis of diabetic retinopathy:a review［J］.Comput Biol Med,2013,43(12):2136-2155.
［5］　TARIQ A,AKRAM M U,SHAUKAT A,KHAN S A.Automated detection and grading of diabetic maculopathy in digital retinal images［J］.J Digit Imaging,2013,26(4):803-812.
［6］　MUSTAFI D,SARAF S S,SHANG Q,OLMOS DE KOO L C.New developments in angiography for the diagnosis and management of diabetic retinopathy［J］.Diabetes Res Clin Pract,2020,167:108361.
［7］　SUN G,WANG X,JIANG J,YI Z,FU M,YANG X,et al.Association of subregional quantitative ultra-widefield fluorescence angiography characteristics with the occurrence of diabetic macular edema and proliferative diabetic retinopathy［J］.Front Med (Lausanne),2021,8:720564.
［8］　ACON D,WU L.Multimodal imaging in diabetic macular edema［J］.Asia Pac J Ophthalmol (Phila),2018，7(1):22-27.
［9］　VAZ-PEREIRA S,MORAIS-SARMENTO T,ENGELBERT M.Update on optical coherence tomography and optical coherence tomography angiography imaging in proliferative diabetic retinopathy［J］.Diagnostics (Basel),2021,11(10):1869.
［10］　JAMPOL L M.Classifications of diabetic macular edema［J］.Eur J Ophthalmol,2020,30(1):6-7.
［11］　邵毅.光学相干断层扫描血管造影(OCTA)在眼科临床的应用［J］.眼科新进展,2017,37(9):801-805.
SHAO Y.Clinical application of optical coherence tomography angiography (OCTA) in ophthalmology［J］.Rec Adv Opthalmol,2017,37(9):801-805.
［12］　MIRSHAHI R,RIAZI-ESFAHANI H,KHALILI POUR E,FADAKAR K,YARMOHAMADI P,ALEMZADEH S A,et al.Differentiating features of OCT angiography in diabetic macular edema［J］.Sci Rep,2021,11(1):23398.
［13］　MOOKIAH M R K,ACHARYA U R,FUJITA H,TAN J H,CHUA C K,BHANDARY S V,et al.Application of different imaging modalities for diagnosis of diabetic macular edema:a review［J］.Comput Biol Med,2015,66:295-315.
［14］　JIN K,PAN X,YOU K,WU J,LIU Z,CAO J,et al.Automatic detection of non-perfusion areas in diabetic macular edema from fundus fluorescein angiography for decision making using deep learning［J］.Sci Rep,2020,10(1):15138.
［15］　DE MOURA J,SAMAGAIO G,NOVO J,ALMUINA P,FERNANDEZ M I,ORTEGA M.Joint diabetic macular edema segmentation and characterization in OCT images［J］.J Digit Imaging,2020,33(5):1335-1351.
［16］　MALERBI F K,MENDES G,BARBOZA N,MORALES P H,MONTARGIL R,ANDRADE R E.Diabetic macular edema screened by handheld smartphone-based retinal camera and artificial intelligence［J］.J Med Syst,2021,46(1):8.
［17］　YIN L,ZHANG D,REN Q,SU X,SUN Z.Prevalence and risk factors of diabetic retinopathy in diabetic patients:a community based cross-sectional study［J］.Medicine (Baltimore),2020,99(9):e19236.
［18］　DIEP T M,TSUI I.Risk factors associated with diabetic macular edema［J］.Diabetes Res Clin Pract,2013,100(3):298-305.
［19］　ELEIWA K T,BAYOUMY A,ELHUSSEINY M A,GAMIL K,SHARAWY A.Longitudinal analysis of subfoveal choroidal thickness after panretinal laser photocoagulation in diabetic retinopathy using swept-source optical coherence tomography［J］.Rom J Ophthalmol,2020,64(3):285-291.
［20］　MIDENA E,MICERA A,FRIZZIERO L,PILOTTO E,ESPOSITO G,BINI S.Sub-threshold micropulse laser treatment reduces inflammatory biomarkers in aqueous humour of diabetic patients with macular edema［J］.Sci Rep,2019,9(1):10034.
［21］　RELHAN N,FLYNN H W.The early treatment diabetic retinopathy study historical review and relevance to today’s management of diabetic macular edema［J］.Curr Opin Ophthalmol,2017,28(3):205-212.
［22］　FRIZZIERO L,CALCIATI A,MIDENA G,TORRESIN T,PARROZZANI R,PILOTTO E,et al.Subthreshold micropulse laser modulates retinal neuroinflammatory biomarkers in diabetic macular edema［J］.J Clin Med,2021,10(14):3134.
［23］　FAZEL F,BAGHERI M,GOLABCHI K,JAHANBANI ARDAKANI H.Comparison of subthreshold diode laser micropulse therapy versus conventional photocoagulation laser therapy as primary treatment of diabetic macular edema［J］.J Curr Ophthalmol,2016,28(4):206-211.
［24］　KOZAK I,OSTER S F,CORTES M A,DOWELL D,HARTMANN K,KIM J S,et al.Clinical evaluation and treatment accuracy in diabetic macular edema using navigated laser photocoagulator NAVILAS［J］.Ophthalmology,2011,118(6):1119-1124.
［25］　CHAUHAN M Z,RATHER P A,SAMARAH S M,ELHUSSEINY A M,SALLAM A B.Current and novel therapeutic approaches for treatment of diabetic macular edema［J］.Cells,2022,11(12):1950.
［26］　FURINO C,BOSCIA F,REIBALDI M,ALESSIO G.Intravitreal therapy for diabetic macular edema:an update［J］.J Ophthalmol,2021,2021:6654168.
［27］　CUNNINGHAM E T,ADAMIS A P,ALTAWEEL M,AIELLO L P,BRESSLER N M,DAMICO D J,et al.A phase II randomized double-masked trial of pegaptanib,an anti-vascular endothelial growth factor aptamer,for diabetic macular edema［J］.Ophthalmology,2005,112(10):1747-1757.
［28］　BAKER C W,GLASSMAN A R,BEAULIEU W T,ANTOSZYK A N,BROWNING D J,CHALAM K V,et al.Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity:a randomized clinical trial［J］.JAMA,2019,321(19):1880-1894.
［29］　WANG X,HE X,QI F,LIU J,WU J.Different anti-vascular endothelial growth factor for patients with diabetic macular edema:a network meta-analysis［J］.Front Pharmacol,2022,13:876386.
［30］　FAGHIHI H,ROOHIPOOR R,MOHAMMADI S F,HOJAT-JALALI K,MIRSHAHI A,LASHAY A,et al.Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema［J］.Eur J Ophthalmol,2008,18(6):941-948.
［31］　SEDZIAK-MARCINEK B,TEPER S,CHEMECKA E,WYLEGAA A,MARCINEK M,BAS M,et al.Diabetic macular edema treatment with bevacizumab does not depend on the retinal nonperfusion presence［J］.J Diabetes Res,2021,2021:6620122.
［32］　RANPURA V,HAPANI S,CHUANG J,WU S.Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients:a meta-analysis of randomized controlled trials［J］.Acta Oncol,2010,49(3):287-297.
［33］　BAKRI S J,LARSON T A,EDWARDS A O.Intraocular inflammation following intravitreal injection of bevacizumab［J］.Graefes Arch Clin Exp Ophthalmol,2008,246(5):779-781.
［34］　YIGIT K,INAN  ,INAN S,DOGAN M,YAVAS G F,CETINKAYA E.Long-term full-field and multifocal electroretinographic changes after treatment with ranibizumab in patients with diabetic macular edema［J］.Int Ophthalmol,2021,41(4):1487-1501.
［35］　CHATZIRALLI I,THEODOSSIADIS G,DIMITRIOU E,KAZANTZIS D,THEODOSSIADIS P.Association between the patterns of diabetic macular edema and photoreceptors’ response after intravitreal ranibizumab treatment:a spectral-domain optical coherence tomography study［J］.Int Ophthalmol,2020,40(10):2441-2448.
［36］　YOZGAT Z,DO GˇAN M,SABANER M C,GOBEKA H H,YAZGAN AKPOLAT S.Impacts of intravitreal anti-VEGF therapy on retinal anatomy and neurophysiology in diabetic macular edema［J］.Int Ophthalmol,2021,41(5):1783-1798.
［37］　OZCALISKAN S,BALCI S,KARASU B,ARTUNAY O.Effect of optical coherence tomography patterns on one-year outcomes of aflibercept therapy for diabetic macular edema［J］.J Coll Physicians Surg Pak,2020,30(2):149-153.
［38］　JOUSSEN A M,POULAKI V,LE M L,KOIZUMI K,ESSER C,JANICKI H,et al.A central role for inflammation in the pathogenesis of diabetic retinopathy［J］.FASEB J,2004,18(12):1450-1452.
［39］　邵毅,王怡欣,漆怡晨.糖尿病性黄斑水肿患者行玻璃体内皮质类固醇植入后眼压的监测和管理——2022年欧洲专家共识解读［J］.眼科新进展,2022,42(5):337-341.
SHAO Y,WANG Y X,QI Y C.Monitoring and management of intraocular pressure in patients with diabetes macular edema after intravitreal corticosteroid implantation - interpretation of the european expert consensus in 2022 ［J］.Rec Adv Ophthalmol,2022,42(5):337-341.
［40］　ROSE M A,VUKICEVIC M,KOKLANIS K,REES G,SANDHU S,ITSIOPOULOS C.Experiences and perceptions of patients undergoing treatment and quality of life impact of diabetic macular edema:a systematic review［J］.Psychol Health Med,2019,24(4):383-401.
［41］　KOLLIAS A N,ULBIG M W.Diabetic retinopathy［J］.Dtsch Arztebl Int,2010,107(5):75-84.
［42］　YUAN Q,LIU Y,XU H,GAO Y,QIN L,GOU Y,et al.Efficacy and safety of single-dose dexamethasone implantation for patients with persistent diabetic macular edema:a systematic review and meta-analysis［J］.Graefes Arch Clin Exp Ophthalmol,2022,260(2):405-413.
［43］　TOTO L,D’ALOISIO R,CHIARELLI A M,DI ANTONIO L,EVANGELISTA F,D’ONOFRIO G,et al.A custom-made semiautomatic analysis of retinal nonperfusion areas after dexamethasone for diabetic macular edema［J］.Transl Vis Sci Technol,2020,9(7):13.
［44］　MATURI R K,GLASSMAN A R,LIU D,BECK R W,BHAVSAR A R,BRESSLER N M,et al.Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema:a DRCR network phase 2 randomized clinical trial［J］.JAMA Ophthalmol,2018,136(1):29-38.
［45］　NASRALLAH F P,JALKH A E,VAN COPPENOLLE F,KADO M,TREMPE C L,MCMEEL J W.The role of the vitreous in diabetic macular edema［J］.Ophthalmology,1988,95(10):1335-1339.
［46］　KIM E J,LIN W V,RODRIGUEZ S M,CHEN A,LOYA A,WENG C Y.Treatment of diabetic macular edema［J］.Curr Diab Rep,2019,19(9):68.
［47］　BEHERA U C,DAS T,SIVAPRASAD S,RANI P K,RAMAN R,AGARWAL M,et al.Is immediate treatment necessary for diabetic macular edema after pars plana vitrectomy for tractional complications of proliferative diabetic retinopathy?［J］.Int Ophthalmol,2021,41(11):3607-3614.
［48］　BERROCAL M H,ACABA-BERROCAL L.Early pars plana vitrectomy for proliferative diabetic retinopathy:update and review of current literature［J］.Curr Opin Ophthalmol,2021,32(3):203-208.
［49］　DIABETIC RETINOPATHY CLINICAL RESEARCH NETWORK WRITING COMMITTEE,HALLER J A,QIN H,APTE R S,BECK R R,BRESSLER N M,et al.Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction［J］.Ophthalmology,2010,117(6):1087-1093.
［50］　MUKAI R,MATSUMOTO H,AKIYAMA H.Surgical outcomes of vitrectomy for intractable diabetic macular edema［J］.Graefes Arch Clin Exp Ophthalmol,2021,259(2):363-368.
［51］　DISTEFANO L N,GARCIA-ARUMI J,MARTINEZ-CASTILLO V,BOIXADERA A.Combination of anti-VEGF and laser photocoagulation for diabetic macular edema:a review［J］.J Ophthalmol,2017,2017:2407037.
［52］　ZHANG L,CHEN X.Efficacy and safety of triamcinolone acetonide injection combined with laser photocoagulation in the treatment of diabetic macular edema:a systematic review and meta-analysis［J］.Ann Palliat Med,2021,10(12):12467-12477.
［53］　KHAN M,AZIZ A A,SHAFI N A,ABBAS T,KHANANI A M.Targeting angiopoietin in retinal vascular diseases:a literature review and summary of clinical trials involving faricimab［J］.Cells,2020,9(8):E1869.
［54］　SHARMA A,KUMAR N,KUPPERMANN B D,BANDELLO F,LOEWENSTEIN A.Understanding biosimilars and its regulatory aspects across the globe:an ophthalmology perspective［J］.Br J Ophthalmol,2020,104(1):2-7.
［55］　SAHNI J,PATEL S S,DUGEL P U,KHANANI A M,JHAVERI C D,WYKOFF C C,et al.Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-a with faricimab in diabetic macular edema:BOULEVARD phase 2 randomized trial［J］.Ophthalmology,2019,126(8):1155-1170.
［56］　SHAW L T,MACKIN A,SHAH R,JAIN S,JAIN P,NAYAK R,et al.Risuteganib-a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema［J］.Expert Opin Investig Drugs,2020,29(6):547-554.
［57］　KITA T,CLERMONT A C,MURUGESAN N,ZHOU Q,FUJISAWA K,ISHIBASHI T,et al.Plasma kallikrein-kinin system as a VEGF-independent mediator of diabetic macular edema［J］.Diabetes,2015,64(10):3588-3599.
［58］　CLERMONT A,CHILCOTE T J,KITA T,LIU J,RIVA P,SINHA S,et al.Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats［J］.Diabetes,2011,60(5):1590-1598.
［59］　SUN J K,MATURI R K,BOYER D S,WELLS J A,GONZALEZ V H,TANSLEY R,et al.One-time intravitreal injection of KVD001,a plasma kallikrein inhibitor,in patients with central-involved diabetic macular edema and reduced vision:an open-label phase 1b study［J］.Ophthalmol Retina,2019,3(12):1107-1109.

相似文献/References:

[1]杜玮 刘子扬 周艳艳 雒雷鸣.糖尿病视网膜病变与血清胆红素水平的关系[J].眼科新进展,2012,32(5):000.
[2]范松涛 卢建民.阿司匹林与糖尿病患者玻璃体出血以及玻璃体切割术疗效的相关性研究[J].眼科新进展,2012,32(11):000.
[3]李艳 李筱荣 袁佳琴 潘斌.糖尿病大鼠视网膜中VEGF、PEDF的表达与血-视网膜屏障损伤[J].眼科新进展,2013,33(1):000.
[4]李朝晖 崔治华 胡晓英 孟丽珠 张敬维.糖尿病视网膜病变激光面积与疗效的分析[J].眼科新进展,2013,33(2):000.
[5]赵倩 金学民.Avastin联合黄斑格栅样光凝治疗糖尿病黄斑水肿的临床研究[J].眼科新进展,2013,33(2):000.
[6]冯冬梅 朱鸿 施彩虹.CXC趋化因子及其受体在糖尿病视网膜病变中的作用[J].眼科新进展,2013,33(6):000.
[7]牛淑玲.糖尿病视网膜病变患者HbAlc、FPG与血小板参数的变化及危险因素分析[J].眼科新进展,2013,33(7):000.
[8]毕春潮 王睿 王建洲 雷春灵 董晓娟 王小莉 薛晓辉.Ad-PEDF对糖尿病视网膜病变大鼠视网膜新生血管的抑制作用[J].眼科新进展,2013,33(8):000.
[9]杨萍 孙书明 李晓鹏.辛伐他汀对糖尿病视网膜病变和炎症因子的影响[J].眼科新进展,2013,33(8):000.
[10]罗文婷 孙大卫.血管黏附蛋白-1在眼科疾病中的研究进展[J].眼科新进展,2013,33(8):000.
[11]曹薇 崔红平 张美萍.23G微切口玻璃体切割手术治疗糖尿病视网膜病变[J].眼科新进展,2013,33(11):000.
[12]邵毅,周召,葛倩敏.糖尿病视网膜病变及黄斑水肿诊疗规范：英国皇家眼科医师学会指南解读[J].眼科新进展,2021,41(7):601.[doi:10.13389/j.cnki.rao.2021.0125]
　SHAO Yi,ZHOU Zhao,GE Qianmin.Consensus interpretation on the diagnosis and treatment of diabetic retinopathy and diabetic macular edema by the The Royal College of Ophthalmologists[J].Recent Advances in Ophthalmology,2021,41(11):601.[doi:10.13389/j.cnki.rao.2021.0125]
[13]徐君,姚丹珍,夏金盈,等.炎症反应在糖尿病视网膜病变中的作用及相关靶点药物的研究进展[J].眼科新进展,2022,42(8):664.[doi:10.13389/j.cnki.rao.2022.0136]
　XU Jun,YAO Danzhen,XIA Jinying,et al.Research progress in the role of inflammatory response in diabetic retinopathy and related targeted drugs[J].Recent Advances in Ophthalmology,2022,42(11):664.[doi:10.13389/j.cnki.rao.2022.0136]
[14]朱君雅,姚文,倪锡森,等.糖尿病性黄斑水肿的病理生理机制：神经血管单元研究现状[J].眼科新进展,2023,43(1):066.[doi:10.13389/j.cnki.rao.2023.0014]
　ZHU Junya,YAO Wen,NI Xinsen,et al.Pathophysiology of diabetic macular edema: current status of neurovascular unit research[J].Recent Advances in Ophthalmology,2023,43(11):066.[doi:10.13389/j.cnki.rao.2023.0014]
[15]许慕东,朱妍,蔡骐,等.总胆红素水平与糖尿病黄斑水肿发病及严重程度的相关性[J].眼科新进展,2023,43(3):216.[doi:10.13389/j.cnki.rao.2023.0044]
　XU Mudong,ZHU Yan,CAI Qi,et al.Correlation between total bilirubin level and occurrence and severity of diabetic macular edema[J].Recent Advances in Ophthalmology,2023,43(11):216.[doi:10.13389/j.cnki.rao.2023.0044]
[16]邵毅,葛倩敏,陈序.糖尿病黄斑水肿患者行醋酸氟轻松治疗规范：2023年专家共识解读[J].眼科新进展,2023,43(10):757.[doi:10.13389/j.cnki.rao.2023.0152]
　SHAO Yi,GE Qianmin,CHEN Xu.Specification on the fluocinolone acetonide treatment for patients with diabetic macular edema: interpretation of expert consensus 2023[J].Recent Advances in Ophthalmology,2023,43(11):757.[doi:10.13389/j.cnki.rao.2023.0152]

备注/Memo

备注/Memo:
中央引导地方科技发展基金（编号：20211ZDG02003）；江西省重点研发项目（编号： 20181BBG70004,20203BBG73059）
更新日期/Last Update: 2022-11-05